Compare INUV & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INUV | XLO |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.2M | 39.4M |
| IPO Year | 1996 | 2021 |
| Metric | INUV | XLO |
|---|---|---|
| Price | $2.97 | $0.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $12.67 | $2.00 |
| AVG Volume (30 Days) | 279.4K | ★ 443.8K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.00 | ★ 60.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,344,000.00 |
| Revenue This Year | $11.72 | $626.78 |
| Revenue Next Year | $3.89 | $79.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.50 |
| 52 Week High | $6.27 | $1.18 |
| Indicator | INUV | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 41.38 |
| Support Level | $2.39 | $0.50 |
| Resistance Level | $3.10 | $0.74 |
| Average True Range (ATR) | 0.30 | 0.04 |
| MACD | 0.17 | 0.00 |
| Stochastic Oscillator | 70.22 | 28.94 |
Inuvo Inc develops and sells information technology solutions for marketing. It develops technology to deliver content and targeted advertisements over the internet. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.